Trials / Recruiting
RecruitingNCT05442710
Recovery From Acute Immune Failure in Septic Shock by Immune Cell Extracorporeal Therapy
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 142 (estimated)
- Sponsor
- Artcline GmbH · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
Evaluation of a novel therapy approach for severe sepsis patients. Subjects randomized into the treatment arm receive treatment with an immune cell perfusion system on top of standard care. This may contribute to the improvement of the impaired organ function of septic shock patients by assisting the impaired immune system (immune competence enhancement = ARTICE)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ARTICE | Extracorporal treatment with purified granulocyte concentrate |
Timeline
- Start date
- 2022-07-24
- Primary completion
- 2026-03-30
- Completion
- 2026-06-30
- First posted
- 2022-07-05
- Last updated
- 2025-05-25
Locations
20 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT05442710. Inclusion in this directory is not an endorsement.